X0609 4 2026-09-28 0001422143 Kura Oncology, Inc. KURA 0001934232 Powl Brian T. false C/O KURA ONCOLOGY, INC. 4930 DIRECTORS PLACE, SUITE 500 SAN DIEGO CA 92121 false true false false Chief Commercial Officer false Common Stock 2026-09-28 4 S false 9020 10.4973 D 160249 D Common Stock 2026-09-28 4 S false 8000 10.5622 D 152249 D Common Stock 2026-09-29 4 S false 15430 10.7487 D 136819 D Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 9/27/25. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on September 27, 2025. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $10.40 to $10.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on September 27, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $10.55 to $10.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Teresa Bair, Attorney-in-fact for Brian Powl 2026-09-29